Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURN-COVID Biobank
2021-005051-37Phase 3Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of casirivimab + imdevimab, sotrovimab, molnupiravir, tixagevimab + cilgavimab and Nirmatrelvir in coronavirus disease 2019 (COVID-19), sponsored by Amsterdam University Medical Center. Primary endpoints: SARS-CoV-2 viral load kinetics with neutralizing monoclonal antibodies and Hospital admission and mortality with neutralizing monoclonal antibodies and antivirals. Started Nov 2021; status: active.
02
Drugs
casirivimab + imdevimabsotrovimabmolnupiravirtixagevimab + cilgavimabNirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-005051-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005051-37.